Novartis Sets a Price of $475000 for CAR T-Cell Therapy – OncLive
OncLive |
Novartis Sets a Price of $475000 for CAR T-Cell Therapy
OncLive Novartis' just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists and … First CAR T-Cell 'Living Drug' Approved by FDA FDA Approves First Gene Therapy For Leukemia FDA approves a 'historic' new type of leukemia treatment |
